Integrating Bispecific Antibodies Into Clinical Practice
Panelists discuss how bispecifics, like teclistamab, are administered at their institutions, the monitoring of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) during step-up dosing, and strategies to improve care transitions between academic centers and community practices. They also highlight the potential for outpatient administration of bispecifics, as seen in the OPTec and Ambulatory Teclistamab studies, emphasizing the benefits of patient convenience and safety.
EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM
EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
EP: 5.Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials
EP: 6.Strategic Use of Bispecific Antibodies in R/R MM
EP: 7.Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
EP: 8.Integrating Bispecific Antibodies Into Clinical Practice
EP: 9.Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025
EP: 10.Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma
Video content above is prompted by the following:
- How is the step-up and treatment doses for bispecifics administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for CRS and ICANS during step-up doing?
- How can we improve the transition of care for patients receiving bispecifics between academic centers and community practices?
- Please comment on the following studies examining outpatient administration of bispecifics and how these strategies might be incorporated in practice: OPTec: Outpatient Step Up Administration of Teclistamab and Ambulatory Teclistamab Administration in R/R MM
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
